Establishing test-retest reliability of an adapted [18 F]fallypride imaging protocol in older people

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 7, 2013, Pages 1098-1103

  Dunn, Joel T ^a   Clark Papasavas, Chloe ^a   Marsden, Paul ^a   Baker, Stacey ^a   Cleij, Marcel ^a   Kapur, Shitij ^a   Kessler, Robert ^b   Howard, Robert ^a   Reeves, Suzanne J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F fallypride; dopamine; imaging; receptors; reliability; test retest

Indexed keywords

DOPAMINE; FALLYPRIDE F 18; TRACER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE RECONSTRUCTION; LIMBIC CORTEX; MALE; MENTAL DISEASE; NEUROIMAGING; NEUROLOGIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REPRODUCIBILITY; STRIATE CORTEX; TEST RETEST RELIABILITY;

AGED; AGING; BENZAMIDES; BRAIN; BRAIN MAPPING; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84880326277     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.55     Document Type: Article

References (39)

1. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258-261
2. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. Curr Pharm Des 2009; 15: 2550-2559
3. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011; 10: 987-1001
4. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544
5. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci 1995; 57: PL103-PL107
6. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M et al. Brain imaging of 18F-fallypride in normal volunteers: Blood analysis, distribution, testretest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 2002; 46: 170-188
7. Olsson H, Halldin C, Swahn CG, Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 1999; 19: 1164-1173
8. Kessler RM, Whetsell WO, Ansari MS, Votaw JR, de Paulis T, Clanton JA et al. Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride. Brain Res 1993; 609: 237-243
9. Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs-An original patient data metaanalysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009; 35: 789-797
10. Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 2011; 17: 97-103
11. Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ et al. The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neurosci Biobehav Rev 2009; 33: 1109-1132
12. Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B et al. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacol 2006; 31: 1016-1026
13. Riccardi P, Park S, Anderson S, Doop M, Ansari MS, Schmidt D et al. Sex differences in the relationship of regional dopamine release to affect and cognitive function in striatal and extrastriatal regions using positron emission tomography and [(1)(8)F]fallypride. Synapse 2011; 65: 99-102
14. Woodward ND, Cowan RL, Park S, Ansari MS, Baldwin RM, Li R et al. Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. Am J Psychiatry 2011; 168: 418-426
15. Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. Neurobiol Dis 2012; 48: 519-525
16. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacol 2008; 33: 3111-3125
17. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental staté. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
18. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacol 2006; 31: 1991-2001
19. Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J et al. Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 2010; 64: 350-362
20. Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Brocheler A et al. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol 2010; 13: 951-960
21. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 1996; 16: 42-52
22. Siessmeier T, Zhou Y, Buchholz HG, Landvogt C, Vernaleken I, Piel M et al. Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med 2005; 46: 964-972
23. Cropley VL, Innis RB, Nathan PJ, Brown AK, Sangare JL, Lerner A et al. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse 2008; 62: 399-408
24. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539
25. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289
26. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M et al. Imaging dopamine receptors in humans with [11C]-(+ )-PHNO: Dissection of D3 signal and anatomy. Neuroimage 2011; 54: 264-277
27. Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 2009; 72: 528-534
28. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285-300
29. Dunn JT, Baker SX, Stone J, Cleij M, Marsden P, O'Doherty M et al. Differential occupancy of striatal versus extrastriatal dopamine D2/D3 receptors by the typical antipsychotic haloperidol in man measured using [18F]fallypridePET. J Psychopharmacol 2010; 24(suppl 3): A33
30. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010; 50: 524-531
31. Dupont WD, Plummer Jr. WD. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11: 116-128
32. Kaasinen V, Vilkman H, Hietala J, Nagren K, Helenius H, Olsson H et al. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging 2000; 21: 683-688
33. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and verylate-onset schizophrenia-like psychosis: An international consensus. International Late-Onset Schizophrenia Group. Am J Psychiatry 2000; 157: 172-178
34. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L et al. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacol 2008; 33: 957-970
35. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: Evidence and mechanisms. J Clin Psychiatry 2009; 70: 397-405
36. Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC. Sensitivity of older patients to antipsychotic motor side effects: A PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009; 17: 255-263
37. Reeves S, Brown R, Matthews D, Howard R, Grasby P. No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010; 81: 119-121
38. Morris ED, Chefer SI, Lane MA, Muzic Jr. RF, Wong DF, Dannals RF et al. Loss of D2 receptor binding with age in rhesus monkeys: Importance of correction for differences in striatal size. J Cereb Blood Flow Metab 1999; 19: 218-229
39. Narendran R, Frankle WG, Mason NS, Rabiner EA, Gunn RN, Searle GE et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse 2009; 63: 447-461